Suggested remit: To appraise the clinical and cost effectiveness of vorasidenib within its marketing authorisation for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6407

Provisional Schedule

Committee meeting 02 July 2025
Expected publication 10 September 2025

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Stakeholders

Companies sponsors Servier Laboratories (vorasidenib)
Others Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
Patient carer groups Astro Brain Tumour Fund
  Brain Tumour Charity
  Brain Tumour Research
  International Brain Tumour Alliance
Professional groups Association of British Neurologists
  Association of Cancer Physicians
  British Neuro-Oncology Society
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Society of British Neurological Surgeons
Associated public health groups None
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
19 November 2024 Topic selection
19 November 2024 Topic routing was discussed at the NICE Prioritisation Board in October 2024. The Board concluded that the topic was suitable for a Technology Appraisal. Please see HST checklist on the project documents tab for further details.
19 November 2024 Invitation to participate
02 September 2024 - 30 September 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6407
02 September 2024 In progress. Scoping commenced.
30 January 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
30 January 2024 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual